NLR_WeightGain_Deidentified Data

There is emerging evidence showing a significant relationship between
overall survival (OS) in non-small cell lung cancer NSCLC patients and weight
change during chemotherapy or chemoradiation. A high neutrophil/lymphocyte
ratio (NLR) at baseline and at follow-up is associated with shorter survival in
cancer patients and may be a surrogate for ongoing inflammation, implicated in cancer
cachexia and tumor progression. The data presented here was collected to explore
potential relationships between OS, serial weights, and serial NLRs in advanced
NSCLC patients receiving chemotherapy.

有越来越多的证据表明，非小细胞肺癌（NSCLC）患者在接受化疗或放化疗过程中的体重变化与总生存期（OS）之间存在显著关联。基线期和随访期的高中性粒细胞/淋巴细胞比率（NLR）与癌症患者的较短生存期相关，可能作为持续炎症的替代指标，而炎症是癌症恶病质和肿瘤进展的诱因之一。此处展示的数据旨在探讨接受化疗的晚期NSCLC患者总生存期、连续体重和连续NLR之间的潜在关系。